Achim Berthele
About
In The Last Decade
Achim Berthele
166 papers receiving 7.5k citations
Hit Papers
Peers
Comparison fields: 5 of 155
- Pathology and Forensic Medicine 3.1k
- Neurology 2.1k
- Cellular and Molecular Neuroscience 1.4k
- Molecular Biology 1.3k
- Physiology 1.2k
Countries citing papers authored by Achim Berthele
This map shows the geographic impact of Achim Berthele's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Achim Berthele with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Achim Berthele more than expected).
Fields of papers citing papers by Achim Berthele
This network shows the impact of papers produced by Achim Berthele. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Achim Berthele. The network helps show where Achim Berthele may publish in the future.
Co-authorship network of co-authors of Achim Berthele
This figure shows the co-authorship network connecting the top 25 collaborators of Achim Berthele. A scholar is included among the top collaborators of Achim Berthele based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Achim Berthele. Achim Berthele is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 1 | |
| 2 | 7 | |
| 3 | 0 | |
| 4 | 4 | |
| 5 | 1 | |
| 6 | 6 | |
| 7 | 1 | |
| 8 | 1 | |
| 9 | 10 | |
| 10 | Neurological implications of COVID-19-results of the LEOSS registry | 1 |
| 11 | 29 | |
| 12 | Efficacy and safety of eculizumab in patients with neuromyelitis optica spectrum disorder previously treated with rituximab: findings from PREVENT | 4 |
| 13 | Regional outcomes of eculizumab treatment in patients with aquaporin-4 immunoglobin G-positive neuromyelitis optica spectrum disorder: findings from the phase 3 PREVENT study | 1 |
| 14 | 2 | |
| 15 | Impact of eculizumab on reported quality of life in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder: findings from the PREVENT study | 2 |
| 16 | Impact of eculizumab on disability measures in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder: phase 3 PREVENT study | 1 |
| 17 | 62 | |
| 18 | Diagnostik und Therapie der Neuromyelitis optica: Konsensusempfehlungen der Neuromyelitis optica Studiengruppe | 0 |
| 19 | 116 | |
| 20 | 46 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.